This is the authors' abstract. We don't add key points for this paper.
PURPOSE: To investigate the role of brain noradrenergic and orexinergic activity in ketamine-induced sedation. METHODS: We used orexin neuron-deficient transgenic rats (orexin/ataxin-3) and wild-type controls. Noradrenaline and orexin levels were measured in the pons, hypothalamus, and cerebral cortex. Ketamine-induced loss-of-righting reflex (LORR) was assessed under modulation of noradrenergic or orexinergic activity. RESULTS: Wild-type rats had higher noradrenaline and orexin levels than transgenic rats across all regions except hypothalamic noradrenaline. Noradrenaline and orexin were correlated in the pons and cortex. Transgenic rats had a shorter LORR duration than wild-type rats (36.3 ± 10.4 vs. 46.7 ± 5.2 min, P = 0.002). Noradrenergic activation via intraperitoneal yohimbine prolonged LORR in both genotypes (wild-type: 38.8 ± 4.9 vs. 71.9 ± 15.3 min at 3.3 mg/kg, P = 0.002; transgenic: 28.1 ± 3.9 vs. 71.9 ± 24.8 min, P < 0.001). Noradrenergic deactivation by DSP4 reduced LORR duration (wild-type: 43.3 ± 2.18 vs. 36.4 ± 6.0 min, P = 0.005). Intracerebroventricular orexin (1.0 nmol) shortened LORR (44.0 ± 16.7 vs. 30.1 ± 15.5 min, P = 0.001), but co-administration of selective orexin type 1 receptor antagonist YNT-1310 (100 nmol) counteracted this effect. Notably, orexin or DSP4 reduced LORR duration in wild-type rats but prolonged it in transgenic rats (e.g., wild-type: 40.8 ± 6.2 vs. 32.5 ± 5.3 min with orexin, P = 0.0001; transgenic 28.6 ± 6.2 vs. 42.1 ± 5.6 min, P = 0.0026). CONCLUSION: Orexin-preserved noradrenergic activity supports the typical ketamine-induced sedation profile, highlighting their interactive role in modulating anesthetic depth.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tonosaki et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: